Fibroblast growth factor-23 in systemic lupus erythematosus patients: Is there a correlation with interleukin-6 and left ventricular mass?

Egyptian Rheumatologist

Mahmoud E. Saraya¹  Marwa M. ElSharkawy²  Ahmed Fayed³  Usama A. Sharaf El Din³  Dina O. Abdulazim⁴  Nahla N. Eesa⁴  Somaya A. Husein⁴ 

[1] Cardiology Department, School of Medicine, Cairo University, Egypt;Chemical Pathology Department, School of Medicine, Cairo University, Egypt;Nephrology Unit, Internal Medicine Department, School of Medicine, Cairo University, Egypt;Rheumatology and Rehabilitation Department, School of Medicine, Cairo University, Egypt;

关键词: Systemic lupus erythematosus;    Interleukin 6;    Fibroblast growth factor 23;    Left ventricular mass index;   

DOI  :  

来源: DOAJ

【 摘 要 】

Background: Chronic kidney disease (CKD) and left ventricular hypertrophy (LVH) are common features of systemic lupus erythematosus (SLE) patients. Fibroblast growth factor 23 (FGF23) is a phosphatonin that steadily increases in serum of CKD patients. High FGF23 is associated with inflammation, CKD progression, and LVH. Aim of the work: To determine any possible role of FGF23 in SLE patients and its relation with interleukin 6 (IL6) and LVH. Patients and methods: Two groups of SLE patients were studied: group I (n = 30) with eGFR > 90 ml/min/1.73 m2 and group II (n = 30) with eGFR <90−>15 ml/min/1.73 m2 as well as 60 controls. IL6, FGF23 and left ventricular mass index (LVMI) were assessed. Results: The mean age of the patients was 25.25 ± 10.65 years (14–55 years) and disease duration was 4.75 ± 5.66 years. Serum FGF23 in SLE patients was comparable to controls (99.6 ± 79.86 vs 139 ± 12.3 pg/mL, p > 0.05). There was no significant difference in serum levels of FGF23 or IL6 between the two SLE groups (106.49 ± 88.2 vs 93.84 ± 74.67 pg/mL, p = 0.56 and 58.6 ± 63.69 vs 55.9 ± 47.97 ng/L respectively, p = 0.85). LVMI was significantly higher in group II than in group I (187.6 ± 81.7 vs 138.6 ± 36.59 respectively, p = 0.0045). FGF23 showed a significant correlation with IL6 (r = 0.78, p < 0.001), but not with LVMI. Conclusion: FGF23 behaves differently in SLE patients; in spite of the significant increase in inflammation and the frequent renal involvement, FGF23 level remains normal in SLE patients raising a possibility of the existence of an FGF23 inhibitor in SLE patients.

【 授权许可】

Unknown